Pelareorep

Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Retrieved on: 
Wednesday, February 2, 2022
Safety, Forward-looking statement, Patient, Progression-free survival, Anal cancer, SAN, NASDAQ, ONC, Cancer, Roche, Clinical trial, Gastrointestinal cancer, DSMB, Biotechnology, Data monitoring committee, American Cancer Society, Research, CEACAM6, COVID-19, DKG, Phenotype, AIO, Pancreatic cancer, TSX, Colorectal cancer, Key Stage 1, Biomarker, Neoplasm, Lymphatic system, ORR, Company, AB, Regulation, Travel, Science, Time, Securities Exchange Act of 1934, Pelareorep, PR, Stage 2, Pharmaceutical industry, Medical imaging, Dietary supplement, Oncolytics Biotech

SAN DIEGO and CALGARY, AB, Feb. 2, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the pancreatic cancer cohort of the phase 1/2 GOBLET study following evaluation by the study's Data Safety Monitoring Board (DSMB). The DSMB noted no safety concerns in these patients and recommended the study proceed as planned. The safety run-in for the trial's third-line metastatic colorectal cancer cohort remains ongoing. 

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the pancreatic cancer cohort of the phase 1/2 GOBLET study following evaluation by the study's Data Safety Monitoring Board (DSMB).
  • The safety run-in for the trial's third-line metastatic colorectal cancer cohort remains ongoing.
  • The study remains ongoing and is expected to enroll patients at 14 clinical trial sites across Germany.
  • "The American Cancer Society, American Cancer Society, Inc., https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
    "Key Statistics for Pancreatic Cancer.

Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Retrieved on: 
Wednesday, February 2, 2022
Safety, Forward-looking statement, Patient, Progression-free survival, Anal cancer, SAN, NASDAQ, ONC, Cancer, Roche, Clinical trial, Gastrointestinal cancer, DSMB, Biotechnology, Data monitoring committee, American Cancer Society, Research, CEACAM6, COVID-19, DKG, Phenotype, AIO, Pancreatic cancer, TSX, Colorectal cancer, Key Stage 1, Biomarker, Neoplasm, Lymphatic system, ORR, Company, AB, Regulation, Travel, Science, Time, Securities Exchange Act of 1934, Pelareorep, PR, Stage 2, Pharmaceutical industry, Medical imaging, Dietary supplement, Oncolytics Biotech

SAN DIEGO and CALGARY, AB, Feb. 2, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the pancreatic cancer cohort of the phase 1/2 GOBLET study following evaluation by the study's Data Safety Monitoring Board (DSMB). The DSMB noted no safety concerns in these patients and recommended the study proceed as planned. The safety run-in for the trial's third-line metastatic colorectal cancer cohort remains ongoing. 

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the pancreatic cancer cohort of the phase 1/2 GOBLET study following evaluation by the study's Data Safety Monitoring Board (DSMB).
  • The safety run-in for the trial's third-line metastatic colorectal cancer cohort remains ongoing.
  • The study remains ongoing and is expected to enroll patients at 14 clinical trial sites across Germany.
  • "The American Cancer Society, American Cancer Society, Inc., https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
    "Key Statistics for Pancreatic Cancer.

Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Retrieved on: 
Thursday, January 27, 2022
COVID-19, Survival, Travel, Breast Cancer Research Foundation, Death, TSX, Securities Exchange Act of 1934, PBMC, Patient, Acceleration, Phenotype, Biotechnology, Paclitaxel, FDA, Chinese Medical Journal, Initiation, Pelareorep, PIK3CA, Research, Cancer, EP4, Cell, Neoplasm, Breast cancer, SAN, Business development, NASDAQ, Clinical trial, ONC, Tissue, Company, Lymphatic system, Woman, Time, AB, III, Global Vision, Regulation, Safety, Forward-looking statement, Roche, Pharmaceutical industry, Medical imaging, Oncolytics Biotech

SAN DIEGO, Calif. and CALGARY, AB, Jan. 27, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer. Dosing in the trial's first dose escalation cohort is complete and no safety issues have been reported. The second dose escalation cohort is the equivalent dose that was administered in the IND-213 study, which reported a near doubling of survival in HR+/HER2- metastatic breast cancer patients.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.
  • The second dose escalation cohort is the equivalent dose that was administered in the IND-213 study, which reported a near doubling of survival in HR+/HER2- metastatic breast cancer patients.
  • "Completion of the bridging trial will allow future Chinese regulatory submissions that will include previously reported clinical data demonstrating pelareorep's potential to substantially benefit metastatic breast cancer patients.
  • The bridging clinical trial is designed to satisfy Chinese regulatory requirements and thereby accelerate pelareorep's development in territories that include China, Hong Kong, and Macau.

Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Retrieved on: 
Thursday, January 27, 2022
COVID-19, Survival, Travel, Breast Cancer Research Foundation, Death, TSX, Securities Exchange Act of 1934, PBMC, Patient, Acceleration, Phenotype, Biotechnology, Paclitaxel, FDA, Chinese Medical Journal, Initiation, Pelareorep, PIK3CA, Research, Cancer, EP4, Cell, Neoplasm, Breast cancer, SAN, Business development, NASDAQ, Clinical trial, ONC, Tissue, Company, Lymphatic system, Woman, Time, AB, III, Global Vision, Regulation, Safety, Forward-looking statement, Roche, Pharmaceutical industry, Medical imaging, Oncolytics Biotech

SAN DIEGO, Calif. and CALGARY, AB, Jan. 27, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer. Dosing in the trial's first dose escalation cohort is complete and no safety issues have been reported. The second dose escalation cohort is the equivalent dose that was administered in the IND-213 study, which reported a near doubling of survival in HR+/HER2- metastatic breast cancer patients.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.
  • The second dose escalation cohort is the equivalent dose that was administered in the IND-213 study, which reported a near doubling of survival in HR+/HER2- metastatic breast cancer patients.
  • "Completion of the bridging trial will allow future Chinese regulatory submissions that will include previously reported clinical data demonstrating pelareorep's potential to substantially benefit metastatic breast cancer patients.
  • The bridging clinical trial is designed to satisfy Chinese regulatory requirements and thereby accelerate pelareorep's development in territories that include China, Hong Kong, and Macau.

Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential

Retrieved on: 
Monday, January 24, 2022
Momentum, CAGR, NMPA, Rutgers University, Multiple myeloma, NYSE, Tislelizumab, NASDAQ, Novartis, Assistant, Robert Wood Johnson Medical School, SNY, Cancer, TSX, PD-1, Oncolytics Biotech, Technology, Rutgers Cancer Institute of New Jersey, Hodgkin lymphoma, Safety, Oncology, TME, TNBC, Heart, Doctor of Philosophy, Johns Hopkins School of Medicine, Letter, Patient, Pelareorep, State, Breast cancer, Precision medicine, BeiGene, Exact sciences, Roche, IRENE, News, GEM, Neoplasm, ONC, Acquisition, CEO, NVS, Immunotherapy, Physician, Pharmaceutical industry, Fine chemical, BC, Medicine, Sanofi

According to Precedence Research , the global cancer immunotherapy market is set to grow at a CAGR of 12.6% to a whopping $277.1 billion by 2030.

Key Points: 
  • According to Precedence Research , the global cancer immunotherapy market is set to grow at a CAGR of 12.6% to a whopping $277.1 billion by 2030.
  • Among the up-and-coming treatments that made significant advancements in 2021 was pelareorep, the flagship immunotherapeutic agent of Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).
  • According to the company's official pipeline , multiple studies are being conducted to test pelareorep in combination with some of the sector's highest-selling cancer drugs to treat various forms of cancer, including breast cancer, gastro-intestinal cancer, and multiple myeloma.
  • The IRENE study remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute ofNew Jerseyand theOhio State UniversityComprehensive Cancer Center.

Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential

Retrieved on: 
Monday, January 24, 2022
Momentum, CAGR, NMPA, Rutgers University, Multiple myeloma, NYSE, Tislelizumab, NASDAQ, Novartis, Assistant, Robert Wood Johnson Medical School, SNY, Cancer, TSX, PD-1, Oncolytics Biotech, Technology, Rutgers Cancer Institute of New Jersey, Hodgkin lymphoma, Safety, Oncology, TME, TNBC, Heart, Doctor of Philosophy, Johns Hopkins School of Medicine, Letter, Patient, Pelareorep, State, Breast cancer, Precision medicine, BeiGene, Exact sciences, Roche, IRENE, News, GEM, Neoplasm, ONC, Acquisition, CEO, NVS, Immunotherapy, Physician, Pharmaceutical industry, Fine chemical, BC, Medicine, Sanofi

VANCOUVER, BC, Jan. 24, 2022 /PRNewswire/ -- USA News Group  -  Within the grand battle against cancer, the use of immunotherapy continues to grow at incredible rates. According to Precedence Research, the global cancer immunotherapy market is set to grow at a CAGR of 12.6% to a whopping $277.1 billion by 2030. According to Johns Hopkins Medicine, precision medicine is at the heart of immunotherapy, however a recent survey of precision oncology programs showed that the rapid pace of advances have caused a major challenge for oncologists. Momentum in the immunotherapy segment continues to draw plenty of investment and interest into the work of developers, including Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exact Sciences Corporation (NASDAQ:EXAS), Sanofi (NASDAQ:SNY), Novartis AG (NYSE:NVS) and BeiGene, Ltd. (NASDAQ:BGNE).

Key Points: 
  • According to Precedence Research , the global cancer immunotherapy market is set to grow at a CAGR of 12.6% to a whopping $277.1 billion by 2030.
  • Among the up-and-coming treatments that made significant advancements in 2021 was pelareorep, the flagship immunotherapeutic agent of Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).
  • According to the company's official pipeline , multiple studies are being conducted to test pelareorep in combination with some of the sector's highest-selling cancer drugs to treat various forms of cancer, including breast cancer, gastro-intestinal cancer, and multiple myeloma.
  • The IRENE study remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute ofNew Jerseyand theOhio State UniversityComprehensive Cancer Center.

New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024

Retrieved on: 
Monday, January 10, 2022
Oncolytics Biotech, CAGR, Pelareorep, Multiple myeloma, Lymphoma, Market, AbbVie, US, NYSE, NASDAQ, Lymphatic system, Leukemia, Azacitidine, News, Therapy, To Market To Market (film), NVS, Cancer, TSX, ABBV, TMO, Novartis, Thermo Fisher Scientific, ONC, Pharmaceutical industry, BC

According to analysts at Markets and Markets, the leukemia therapeutics market is projected to reach US$17.1 billion by 2024 , growing at a CAGR of 6.8%.

Key Points: 
  • According to analysts at Markets and Markets, the leukemia therapeutics market is projected to reach US$17.1 billion by 2024 , growing at a CAGR of 6.8%.
  • Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments, as indicated with these latest preclinical results.
  • Compared to either treatment alone, treatment with pelareorep plus azacitidine led to a statistically significant reduction (p
  • The combination of pelareorep and azacitidine dramatically upregulated multiple genes known to drive anti-cancer immune responses such asIFN1, BATF2, IL-12, CCL2, TLR3,andPD-L1.

New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024

Retrieved on: 
Monday, January 10, 2022
Oncolytics Biotech, CAGR, Pelareorep, Multiple myeloma, Lymphoma, Market, AbbVie, US, NYSE, NASDAQ, Lymphatic system, Leukemia, Azacitidine, News, Therapy, To Market To Market (film), NVS, Cancer, TSX, ABBV, TMO, Novartis, Thermo Fisher Scientific, ONC, Pharmaceutical industry, BC

According to analysts at Markets and Markets, the leukemia therapeutics market is projected to reach US$17.1 billion by 2024 , growing at a CAGR of 6.8%.

Key Points: 
  • According to analysts at Markets and Markets, the leukemia therapeutics market is projected to reach US$17.1 billion by 2024 , growing at a CAGR of 6.8%.
  • Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments, as indicated with these latest preclinical results.
  • Compared to either treatment alone, treatment with pelareorep plus azacitidine led to a statistically significant reduction (p
  • The combination of pelareorep and azacitidine dramatically upregulated multiple genes known to drive anti-cancer immune responses such asIFN1, BATF2, IL-12, CCL2, TLR3,andPD-L1.

Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks

Retrieved on: 
Wednesday, December 8, 2021
Merck, Oncolytics Biotech, Merck Group, Tafasitamab, Lung cancer, News, Self-signed certificate, Breast cancer, Therapy, CEO, TSX, National Institute, Eli Lilly and Company, 2021 Essex County Council election, Hematology, Lenalidomide, Oncology, Epacadostat, IRENE, Pfizer, NICE, Gilead Sciences, Cancer Drugs Fund, Lymphoma, Ponatinib, Patient, National Institute for Health and Care Excellence, NYSE, GILD, Immunotherapy, Phase, CDF, ONC, Cancer, Pelareorep, Principal investigator, TACSTD2, Neoplasm, Sacituzumab govitecan, ASH, Bristol Myers Squibb, Congress, Principal, TNBC, LLY, Safety, Internal medicine, Science, CAGR, MD, RET, Clinical trial, Survival, NASDAQ, Doctor of Philosophy, NSCLC, Pharmaceutical industry

Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis .

Key Points: 
  • Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis .
  • "These milestones include the reporting of new clinical biomarker data from our AWARE-1 breast cancer study, which we are pleased to be announcing today.
  • It also indicates that changes in peripheral blood T cell populations may be predictive of patient response.
  • We look forward to working with her team in our advanced breast cancer clinical trial to accelerate patient recruitment."

Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks

Retrieved on: 
Wednesday, December 8, 2021
Merck, Oncolytics Biotech, Merck Group, Tafasitamab, Lung cancer, News, Self-signed certificate, Breast cancer, Therapy, CEO, TSX, National Institute, Eli Lilly and Company, 2021 Essex County Council election, Hematology, Lenalidomide, Oncology, Epacadostat, IRENE, Pfizer, NICE, Gilead Sciences, Cancer Drugs Fund, Lymphoma, Ponatinib, Patient, National Institute for Health and Care Excellence, NYSE, GILD, Immunotherapy, Phase, CDF, ONC, Cancer, Pelareorep, Principal investigator, TACSTD2, Neoplasm, Sacituzumab govitecan, ASH, Bristol Myers Squibb, Congress, Principal, TNBC, LLY, Safety, Internal medicine, Science, CAGR, MD, RET, Clinical trial, Survival, NASDAQ, Doctor of Philosophy, NSCLC, Pharmaceutical industry

VANCOUVER, BC, Dec. 8, 2021 /PRNewswire/ -- USA News Group  -  Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit nearly $310 billion by 2030, according to Allied Analytics. Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis. Last December, biotechs working on breast cancer treatments saw their shares soar. This year has continued that momentum, with multiple biotech companies driving progress in the fight against cancer, including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), BriaCell Therapeutics Corp. (NASDAQ:BCTX), Gilead Sciences, Inc. (NASDAQ:GILD), and Eli Lilly and Company (NYSE:LLY).

Key Points: 
  • Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis .
  • "These milestones include the reporting of new clinical biomarker data from our AWARE-1 breast cancer study, which we are pleased to be announcing today.
  • It also indicates that changes in peripheral blood T cell populations may be predictive of patient response.
  • We look forward to working with her team in our advanced breast cancer clinical trial to accelerate patient recruitment."